Literature DB >> 34035714

Clinical Implications of the Recent Dose-Ranging Studies of Adalimumab.

Brian Feagan1.   

Abstract

Entities:  

Year:  2020        PMID: 34035714      PMCID: PMC8132697     

Source DB:  PubMed          Journal:  Gastroenterol Hepatol (N Y)        ISSN: 1554-7914


× No keyword cloud information.
  3 in total

1.  Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis.

Authors:  William J Sandborn; Gert van Assche; Walter Reinisch; Jean-Frederic Colombel; Geert D'Haens; Douglas C Wolf; Martina Kron; Mary Beth Tighe; Andreas Lazar; Roopal B Thakkar
Journal:  Gastroenterology       Date:  2011-11-04       Impact factor: 22.682

2.  Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial.

Authors:  Jean-Frédéric Colombel; William J Sandborn; Paul Rutgeerts; Robert Enns; Stephen B Hanauer; Remo Panaccione; Stefan Schreiber; Dan Byczkowski; Ju Li; Jeffrey D Kent; Paul F Pollack
Journal:  Gastroenterology       Date:  2006-11-29       Impact factor: 22.682

3.  Dosage adjustment during long-term adalimumab treatment for Crohn's disease: clinical efficacy and pharmacoeconomics.

Authors:  William J Sandborn; Jean-Frédéric Colombel; Stefan Schreiber; Scott E Plevy; Paul F Pollack; Anne M Robinson; Jingdong Chao; Parvez Mulani
Journal:  Inflamm Bowel Dis       Date:  2011-01       Impact factor: 5.325

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.